Related references
Note: Only part of the references are listed.DNA Repair Gene Polymorphisms Predict Favorable Clinical Outcome in Advanced Non-Small-Cell Lung Cancer
Aristea Kalikaki et al.
CLINICAL LUNG CANCER (2009)
Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics
David R. Gandara et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin -: Treated advanced non-small cell lung cancer patients
Carmelo Tibaldi et al.
CLINICAL CANCER RESEARCH (2008)
Genetic polymorphisms and treatment response in advanced non-small cell lung cancer
Dan Su et al.
LUNG CANCER (2007)
DNA repair and survival in lung cancer - The two faces of Janus
Adi F. Gazdar
NEW ENGLAND JOURNAL OF MEDICINE (2007)
被撤回的出版物: Genomic signatures to guide the use of chemotherapeutics (Retracted article. See vol. 17, pg. 135, 2011)
Anil Potti et al.
NATURE MEDICINE (2006)
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
Ken A. Olaussen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapyin advanced nonsmall cell lung cancer
Richard Booton et al.
CANCER (2006)
Chemotherapy in advanced non-small cell lung cancer
T Evans
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Molecular predictors of response to chemotherapy in lung cancer
R Rosell et al.
SEMINARS IN ONCOLOGY (2004)
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer
D Isla et al.
ANNALS OF ONCOLOGY (2004)
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
S Gurubhagavatula et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy
JS Ryu et al.
LUNG CANCER (2004)
Xpd/Ercc2 regulates CAK activity and mitotic progression
J Chen et al.
NATURE (2003)
Share Paper
